TNFRSF11A and breast cancer: To confirm the immunomodulatory role of RANK pathway inhibition in the clinical setting, we analyzed denosumab-treated BC clinical samples from the D-BEYOND study (NCT01864798): a prospective, pre-operative window-of-opportunity, single-arm, multi-center trial assessing the effect of denosumab in premenopausal women with early-stage BC.